These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33863779)

  • 1. mTOR Activation Initiates Renal Cell Carcinoma Development by Coordinating ERK and p38MAPK.
    Wu H; He D; Biswas S; Shafiquzzaman M; Zhou X; Charron J; Wang Y; Nayak BK; Habib SL; Liu H; Li B
    Cancer Res; 2021 Jun; 81(12):3174-3186. PubMed ID: 33863779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR inhibition induces compensatory, therapeutically targetable MEK activation in renal cell carcinoma.
    Bailey ST; Zhou B; Damrauer JS; Krishnan B; Wilson HL; Smith AM; Li M; Yeh JJ; Kim WY
    PLoS One; 2014; 9(9):e104413. PubMed ID: 25180793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
    Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
    Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1.
    Zhang C; Duan Y; Xia M; Dong Y; Chen Y; Zheng L; Chai S; Zhang Q; Wei Z; Liu N; Wang J; Sun C; Tang Z; Cheng X; Wu J; Wang G; Zheng F; Laurence A; Li B; Yang XP
    Clin Cancer Res; 2019 Nov; 25(22):6827-6838. PubMed ID: 31383732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
    Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
    Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
    Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
    J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
    Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
    Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miRNA‑205‑5p functions as a tumor suppressor by negatively regulating VEGFA and PI3K/Akt/mTOR signaling in renal carcinoma cells.
    Huang J; Wang X; Wen G; Ren Y
    Oncol Rep; 2019 Nov; 42(5):1677-1688. PubMed ID: 31545453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.
    Luo YD; Fang L; Yu HQ; Zhang J; Lin XT; Liu XY; Wu D; Li GX; Huang D; Zhang YJ; Chen S; Jiang Y; Shuai L; He Y; Zhang LD; Bie P; Xie CM
    J Hepatol; 2021 Jan; 74(1):96-108. PubMed ID: 32738450
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CEP55 promotes epithelial-mesenchymal transition in renal cell carcinoma through PI3K/AKT/mTOR pathway.
    Chen H; Zhu D; Zheng Z; Cai Y; Chen Z; Xie W
    Clin Transl Oncol; 2019 Jul; 21(7):939-949. PubMed ID: 30607788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NKAP promotes renal cell carcinoma growth via AKT/mTOR signalling pathway.
    Ma Q; Hou L; Gao X; Yan K
    Cell Biochem Funct; 2020 Jul; 38(5):574-581. PubMed ID: 32032976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-21 Regulates the Proliferation, Differentiation, and Apoptosis of Human Renal Cell Carcinoma Cells by the mTOR-STAT3 Signaling Pathway.
    Liang T; Hu XY; Li YH; Tian BQ; Li ZW; Fu Q
    Oncol Res; 2016; 24(5):371-380. PubMed ID: 27712594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis.
    Gan B; Lim C; Chu G; Hua S; Ding Z; Collins M; Hu J; Jiang S; Fletcher-Sananikone E; Zhuang L; Chang M; Zheng H; Wang YA; Kwiatkowski DJ; Kaelin WG; Signoretti S; DePinho RA
    Cancer Cell; 2010 Nov; 18(5):472-84. PubMed ID: 21075312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4/6 inhibitors dephosphorylate RNF26 to stabilize TSC1 and increase the sensitivity of ccRCC to mTOR inhibitors.
    Liu X; Li W; Yi L; Wang J; Liu W; Cheng H; Ren S
    Br J Cancer; 2024 Aug; 131(3):444-456. PubMed ID: 38890443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The mammalian target of rapamycin pathway is widely activated without PTEN deletion in renal cell carcinoma metastases.
    Abou Youssif T; Fahmy MA; Koumakpayi IH; Ayala F; Al Marzooqi S; Chen G; Tamboli P; Squire J; Tanguay S; Sircar K
    Cancer; 2011 Jan; 117(2):290-300. PubMed ID: 20830770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MiR-144 inhibits cell proliferation of renal cell carcinoma by targeting MTOR.
    Xiang C; Cui SP; Ke Y
    J Huazhong Univ Sci Technolog Med Sci; 2016 Apr; 36(2):186-192. PubMed ID: 27072960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreas-specific activation of mTOR and loss of p53 induce tumors reminiscent of acinar cell carcinoma.
    Kong B; Cheng T; Qian C; Wu W; Steiger K; Cao J; Schlitter AM; Regel I; Raulefs S; Friess H; Erkan M; Esposito I; Kleeff J; Michalski CW
    Mol Cancer; 2015 Dec; 14():212. PubMed ID: 26683340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.
    Chen CH; Fong LWR; Yu E; Wu R; Trott JF; Weiss RH
    Oncogene; 2017 Jun; 36(25):3588-3598. PubMed ID: 28166200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.
    Li H; Argani P; Halper-Stromberg E; Lotan TL; Merino MJ; Reuter VE; Matoso A
    Am J Surg Pathol; 2023 Nov; 47(11):1267-1273. PubMed ID: 37661807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.